Biote price target lowered to $3 from $4.50 at Roth Capital

Roth Capital lowered the firm’s price target on Biote (BTMD) to $3 from $4.50 and keeps a Buy rating on the shares. The company’s Q4 results and 2026 guide showed some progress, but continued procedure and certainty in planned operating expenditure investments are likely to keep the stock range-bound in the near term, the analyst tells investors in a research note.